Efficacy and safety of oxcarbazepine in epileptic children.
10.3345/kjp.2008.51.2.162
- Author:
Hye Kyung SHIN
1
;
Yoon LEE
;
Jee Yeon LEE
;
Wooksun CHOI
;
So Hee EUN
;
Baik Lin EUN
;
Young Sook HONG
;
Joo Won LEE
Author Information
1. Department of Pediatrics, Kwangmyung-Sungae Hospital, Kwangmyung, Korea.
- Publication Type:Original Article
- Keywords:
Oxcarbazepine;
Efficacy;
Safety;
Child
- MeSH:
Carbamazepine;
Child;
Dizziness;
Exanthema;
Freedom;
Headache;
Humans;
Hyponatremia;
Korea;
Light;
Neurology;
Retrospective Studies;
Seizures;
Sleep Stages
- From:Korean Journal of Pediatrics
2008;51(2):162-169
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Oxcabarzepine (OXC), newly recommended antiepileptic drug, has been prescribed for patients with partial seizures and generalized tonic clonic seizures in Korea from 1999. There are limited reports about an efficacy of OXC therapy in epileptic children in Korea. This study evaluated the efficacy and safety of OXC in the light of our experience. METHODS: The patients, who had visited the pediatric neurology clinic of Korea University Guro Hospital from January 2001 to December 2006, were included. The data of 144 patients who were administrated OXC as monotherapy or polytherapy, was summarized retrospectively and we evaluated the efficacy and safety of OXC. RESULTS: After 6 months of OXC therapy, 77 patients (53.5%, n=144) achieved seizure freedom, 48 patients (33.3%) experienced >50% improvement. After 12 months of OXC therapy, cessation of seizure was observed in 88 patients (61.1%, n=133), and 27 patients (18.8%) manifested an improvement. Monotherapy group showed superior efficacy to polytherapy one. The frequent side effects of OXC were drowsiness (20.1%), headache (12.5%), dizziness (9.7%) and rash (8.3%). They did not related to patient's age or sex, and dosage of OXC. Twenty four patients (16.7%) experienced hyponatremia, but which were neither symptomatic nor significant one. CONCLUSION: The efficacy and safety of OXC in our patients were excellent and had less significant side effects than established international one. We expect this report contributes toward OXC therapy in epileptic children.
